Chemomab Therapeutics Ltd.
CMMB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CMMB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CMMB
Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on developing nebokitug, a novel therapy for fibrotic and inflammatory diseases such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), with no approved products and no revenue to date.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$19.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 2 clinical trials for Chemomab Therapeutics Ltd..
Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on developing nebokitug, a novel therapy for fibrotic and inflammatory diseases such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), with no approved products and no revenue to date.
- Chemomab is a clinical-stage biopharmaceutical company with no products approved for commercial sale and has not generated any revenue [sec · filed 2026-03-23].
- The company's lead product candidate is nebokitug, being developed for primary sclerosing cholangitis (PSC) and potentially systemic sclerosis (SSc) [sec · filed 2026-03-23].
- As of 2025-12-31, Chemomab reported cash and equivalents of $7.6 million and shareholders' equity of $13.5 million [sec].
- The company expects its existing cash to fund operations only through the end of the first quarter of 2027, raising substantial doubt about its ability to continue as a going concern [sec · filed 2026-03-23].
- Chemomab has incurred significant losses since inception and anticipates increasing operating losses as it advances nebokitug through clinical development [sec · filed 2026-03-23].
What works
- Chemomab has optimized its clinical development plan for nebokitug to maximize clinical information and support future registration trials, potentially decreasing overall program risk [sec · filed 2026-03-23].
- The company's management team is described as highly experienced in managing clinical trials across a wide range of indications and geographies [sec · filed 2026-03-23].
What to weigh
- Chemomab has a limited operating history, no approved products, and no revenue, making it difficult to evaluate its prospects and likelihood of success [sec · filed 2026-03-23].
- The company will need substantial additional funding to complete development of nebokitug or any other product candidates, and there is no assurance such financing will be available [sec · filed 2026-03-23].
- Existing cash is only expected to fund operations through the end of the first quarter of 2027, creating substantial doubt about the company's ability to continue as a going concern [sec · filed 2026-03-23].
From the filings
Quoted directly from source documents.
Chemomab has no approved products and no revenue.
“We currently have no products that are app”
SEC filings · March 23, 2026
The company expects to need substantial additional funding.
“we will need to raise substantial additional funding through public or private equity or debt transactions or a strategic combination or partnership”
SEC filings · March 23, 2026
Cash runway is limited to early 2027.
“We believe that our existing cash, cash equivalents and bank deposits will enable us to fund our operating expenses and capital expenditure requirements through the end of the first quarter of 2027”
SEC filings · March 23, 2026
Nebokitug is the lead product candidate for PSC and SSc.
“Advance our lead product, nebokitug, for the treatment of PSC and potentially SSc, through clinical development to approval”
SEC filings · March 23, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Existing cash expected to fund operations only through Q1 2027, raising substantial doubt about ability to continue as a going concern [sec · filed 2026-03-23].
- Dependence on nebokitug — Business is highly dependent on the success of nebokitug, which requires significant additional clinical development and regulatory approval [sec · filed 2026-03-23].
- No revenue or approved products — Company has no products approved for commercial sale and has not generated any revenue, with a limited operating history [sec · filed 2026-03-23].
- Need for additional financing — Substantial additional funding is required to complete development of nebokitug, with no assurance of raising such capital [sec · filed 2026-03-23].
What to watch
- Ability to secure additional financing to extend cash runway beyond Q1 2027 [sec · filed 2026-03-23].
- Progress of nebokitug clinical trials in PSC and potentially SSc, including enrollment and data readouts [sec · filed 2026-03-23].
- Any strategic partnership or licensing deals to fund further development [sec · filed 2026-03-23].
- Regulatory interactions with the FDA or other agencies regarding nebokitug's development path [sec · filed 2026-03-23].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Chemomab Therapeutics Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Chemomab Therapeutics Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 0.12
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$458K
| Holder | Shares | Value |
|---|---|---|
| adar1 capital management, llc | 80,000 | $126K |
| citadel advisors llc | 64,182 | $101K |
| kestra private wealth services, llc | 61,710 | $97K |
| xtx topco ltd | 18,629 | $29K |
| rhumbline advisers | 18,366 | $29K |
| smartharvest portfolios, llc | 14,566 | $23K |
| susquehanna international group, llp | 13,491 | $21K |
| bnp paribas financial markets | 8,425 | $13K |
| gamma investing llc | 7,579 | $12K |
| morgan stanley | 4,575 | $7K |
Showing top 10 of 13 institutional holders of Chemomab Therapeutics Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.7%
- Days to cover
- 1.3
- Shares short
- 47,374
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CMMB short interestFrequently asked questions
What is the AI investment thesis for Chemomab Therapeutics Ltd.?
Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on developing nebokitug, a novel therapy for fibrotic and inflammatory diseases such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), with no approved products and no revenue to date.
Who is the CEO of Chemomab Therapeutics Ltd.?
Dr. Adi Mor George Ph.D. is the chief executive officer of Chemomab Therapeutics Ltd. (CMMB).
Where is Chemomab Therapeutics Ltd. headquartered?
Chemomab Therapeutics Ltd. (CMMB) is headquartered in Tel Aviv-Yafo, Israel.
What therapeutic areas does Chemomab Therapeutics Ltd. focus on?
Chemomab Therapeutics Ltd. develops therapies across Immunology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.